참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Fluoxetine | HCID 3386 | — |
| 반응물 | 1-Propanone, 3-(dimethylamino)-1-phenyl-, hydrochloride (1:1) | HCID 92844 | — |
| 반응물 | Diboron | HCID 6328200 | — |
| 생성물 | 3-(Dimethylamino)-1-phenylpropan-1-ol | HCID 110665 | — |
반응 단계
In the process for the preparation of fluoxetine, as in U.S. Pat. No. 4,314,081, β-dimethylaminopropiophenone hydrochloride is used as a starting material which, after the liberation of the base, is hydrogenated with diborane, B2H4. The N,N-dimethyl-3-hydroxy-3-phenylpropylamine produced in the reaction is allowed to react with thionyl chloride in chloroform containing hydrochloric acid yielding N,N-dimethyl-3-phenyl-3-chloropropylamine. This compound is allowed to react under alkaline conditions with p-trifluoro-methylphenol by heating the mixture under reflux for 5 days and nights, after which N,N-dimethyl-3-p-trifluoromethylphenoxy-3-phenylpropylamine is produced. This compound is N-demethylated with the aid of cyanogen bromide, yielding N-methyl-N-cyano-3-(p-trifuoromethylphenoxy)-phenylpropylamine. The N-cyano group is removed from this compound by heating for 20 hours at 130° C. under reflux in a mixture of potassium hydroxide and ethylene glycol. The reaction mixture is extracted with ether and the ether phase is evaporated to dryness. The residue could further be transformed in a known manner into a pharmaceutically acceptable salt of fluoxetine.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US05166437 |
|---|
| 출처 데이터셋 | uspto-grants-1992_11 |
|---|
| ORD ID | ord-6a6acbf10e9d48e18c50e2ffd34738cf |
|---|
| 출처 메모 | uspto-grants-1992_11 |
|---|